Atossa Genetics Announces First Quarter 2015 Financial Results and Provides Company Update
Achieves Total Revenue for Q1 2015 of $1.9 Million; Conference Call to Be Held Today at 4:30 pm Eastern Time
(firmenpresse) - SEATTLE, WA -- (Marketwired) -- 05/13/15 -- Atossa Genetics Inc. (NASDAQ: ATOS) today announced first quarter 2015 financial results and provided an update on recent company developments.
Steve Quay, President and CEO, commented, "We have made tremendous progress towards achieving our 2015 objectives by launching the ForeCYTE Breast Aspirator in the European Union and the FullCYTE Breast Aspirator in the United States. We engaged key national distributors in the United States and are seeing very strong growth with our pharmacogenomics tests. We look forward to continued progress towards our other key 2015 objectives, which are to begin clinical studies in a therapeutic using our devices and growing our revenue with our products and services."
Important recent corporate developments include the following:
Launched the ForeCYTE Breast Aspirator in the European Union
Launched the FullCYTE Breast Aspirator in the United States
Engaged two leading national distributors in the United States
Hired biopharmaceutical industry veteran Cindy Atha as Vice President of Sales and Marketing
Secured in-network contract with Meridian Health Plan of Michigan
The College of American Pathologists certified our laboratory, The National Reference Laboratory for Breast Health Inc.
Revenue for the three months ended March 31, 2015 totaled $1,873,268, consisting of mainly pharmacogenomics testing, compared to $24,124 in revenue in the same period in 2014 from additional cash collections on NAF cytology tests. Total cost of revenue for the three months ended March 31, 2015 was $1,207,954 and consisted of costs relating to pharmacogenomics testing services, compared to $0 for the same period in 2014.
Gross profit for the three months ended March 31, 2015 was $665,314, attributable to pharmacogenomics testing, compared to $24,124 gross profit in the same period in 2014.
Total operating expenses were $3,949,190 for the three months ended March 31, 2015, consisting of general and administrative (G&A) expenses of $2,605,111, R&D expenses of $797,225, and selling expenses of $546,854 representing an increase of $1,514,141, or 62%, from $2,435,049 for the three months ended March 31, 2014, which consisted of G&A expenses of $1,774,708, R&D expenses of $422,503, and selling expenses of $237,838.
Management will host a conference call today, Wednesday, May 13, 2015 at 4:30 pm Eastern time to review financial results and corporate highlights. Following management''s formal remarks, there will be a question and answer session. To listen to the call by phone, interested parties within the U.S. should call 1-866-652-5200 and international callers should call 1-412-317-6060. All callers should ask for the Atossa Genetics conference call. The conference call will also be available through a live webcast at . Details for the webcast may be found on the Company''s IR events page at .
A replay of the call will be available approximately one hour after the end of the call through June 14, 2015. The replay can be accessed via Atossa''s website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada toll free at 855-669-9658. The replay conference ID number is 10065375.
Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health Inc. The laboratory services and the Company''s medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For more information, please visit .
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory approvals needed by Atossa to sell its products, responses to regulatory matters, Atossa''s ability to achieve its objectives, continue to manufacture and sell its products, recalls of products, the safety and efficacy of Atossa''s products and services, performance of distributors, whether Atossa can launch and commercialize in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa''s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. Atossa does not undertake any obligation to update any forward-looking statement.
Atossa Genetics Inc.
Kyle Guse
CFO and General Counsel
(O) 800-351-3902
Investor Relations:
CorProminence LLC
Scott Gordon
President
516-222-2560
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.05.2015 - 14:01 Uhr
Sprache: Deutsch
News-ID 1358699
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SEATTLE, WA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Atossa Genetics Announces First Quarter 2015 Financial Results and Provides Company Update
"
steht unter der journalistisch-redaktionellen Verantwortung von
Atossa Genetics Inc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
